Cochlear Limited (CHEOF) Fair Value & Analysis
Healthcare · US · Market cap $5.0B
Cochlear Limited
CHEOF · US
Fair value as of: Jul 15, 2026
From 26 valuation models · updated 8 days ago
Fair value updated Jul 15, 2026, revised from $63.39 to $64.17 (+1.2%) since Jun 24, 2026. Share price +11.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $64.39 – $224.37 · fair‑value band $35.16 – $92.37 · the $84.74 price screens above the $64.17 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Cochlear Limited (CHEOF) currently trades at $84.74, while our model-based Fair Value estimate is $64.17, implying the stock looks roughly 24.3% overvalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Cochlear Limited generated revenue of $2.3B at a net margin of 14.8%. Revenue declined 0.4% year over year. It earns a return on equity of 18.2%. The balance sheet holds a net cash position of $40.0M. Fundamentals as of Jul 15, 2026
Our scenario range runs from $35.16 (bear case) to $92.37 (bull case); at $84.74, the current price sits within that range. The share trades about 58% below its 52-week high and 32% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -24%, CHEOF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor and Baha implant; and accessories, such as wireless devices and Nucleus water-safe accessories. The company was founded in 1981 and is headquartered in Sydney, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cochlear Limited reported revenue of $2.3B in FY2025 versus $1.5B in FY2021, a compound +11.8%/yr. Reported net income was $389M in FY2025, compounding +4.5%/yr from FY2021.
Is CHEOF fairly valued? → Check now
Recent news
- Cochlear introduces the new Osia® 3 Sound Processor
- Don't Miss the Moments That Matter This Summer: Hearing Experts and Cochlear Encourage People to Check Their Hearing Health
- [Latest] Global Ear Health Market Size/Share Worth USD 16.87 Billion by 2035 at a 5.7% CAGR: Healthcare Foresights (Analysis, Outlook, Leade
- Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $89.17 | $70.59 | -21% |
| Stryker Corporation SYK | $308.84 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$213.40 | R$31.21 | -85% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EWL | €74.82 | €32.56 | -56% |
| Siemens Healthineers AG SEMHF | $39.91 | $48.29 | +21% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥144.39 | ¥105.08 | -27% |
| STERIS plc S1TE34 | R$52.14 | R$39.50 | -24% |
| Zimmer Biomet Holdings Z1BH34 | R$116.16 | R$85.57 | -26% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cochlear Limited (CHEOF) undervalued?
What is the fair value of CHEOF?
What is the quality score of CHEOF?
What is the revenue of Cochlear Limited (CHEOF)?
What is the net profit margin of CHEOF?
Does Cochlear Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Cochlear Limited analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.